CARM1 and neoplasm: EZM2302 demonstrates in vitro anti-proliferative activity consistent with specific methyl mark inhibition; displays dose-dependent inhibition of CARM1 substrate methylation in vivo; and induces growth inhibition of human multiple myeloma tumor xenografts in mice after oral dosing.